ERBB2 and gastric cancer: Trastuzumab, a human epidermal growth factor receptor 2 (HER2)–targeted agent, was the first molecular therapy developed for unresectable advanced or recurrent gastric cancer and has become the standard first-line treatment, significantly improving the overall survival (OS) of patients with unresectable or recurrent HER2-positive gastric cancer.1)